Cancer Genetics, Sayre Therapeutics in distribution agreement

To commercialise CGI’s Proprietary FDA-cleared Tissue of Origin test throughout India and South Asia

Cancer Genetics has signed an exclusive distribution agreement that provides Sayre Therapeutics sales and marketing rights of Cancer Genetics’ Tissue of Origin test in India and South Asia. TOO data generated by the use of the test in India will contribute to the expansion of CGI’s knowledge base to further validate the clinical utility of the test on a global basis.

CGI’s TOO is a microarray-based gene expression test that aids in identifying challenging tumours, including metastatic, poorly differentiated, and undifferentiated cancers. It is able to report the tissue of origin of 15 of the most common tumour types (thyroid, breast, non-small cell lung, pancreatic, gastric, colorectal, liver, bladder, kidney, non-Hodgkin’s lymphoma, melanoma, ovarian, sarcoma, testicular germ cell, and prostate tumors), representing 58 cancer morphologies and covering 90 per cent of all solid tumours. TOO leads to a change in treatment 65 per cent of the time.